ClinicalTrials.gg
CompletedNCT06019338Updated Dec 10, 2024

A Study to Validate a Pain Diary for Patient With Trigeminal Neuralgia

An observational study in Trigeminal Neuralgia, sponsored by Noema Pharma AG. Completed at 2 sites in 2 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-12-10.

Sponsored by Noema Pharma AG · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Trigeminal Neuralgia with a site in United States — 7 open to participants now, 11 under way, 1 of them phase 3. Trigeminal Neuralgia · United States.

Started
2021
with 2 others
Observational
8 of 34
4 open now
Registered
29th of 34
by date
Lead sponsor
2 of 34
Noema Pharma AG

Among the 34 studies in Trigeminal Neuralgia with a site in United States, this one is one of 3 that started in 2021, is one of 8 observational ones, and was the 29th registered.

Trigeminal Neuralgia

140 studies on the registry are indexed under Trigeminal Neuralgia; 44 are open to participants now.

Browse Trigeminal Neuralgia studies →

Open to participants now

7 of the 34 studies in Trigeminal Neuralgia with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 27 Trigeminal Neuralgia studies recruiting now, 18 (67%) set no upper age limit and 3 (11%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 40 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Trigeminal Neuralgia with a site in United States, or all of them as a file.
02

Study summary

The aim of the study is to establish the validity of a patient reported diary in TN . The following objectives have been identified:

  1. To generate evidence to support diary content validity by performing qualitative research studies with TN patients and Healthcare Professionals (HCPs).
  2. To provide further support to the diary, sensitivity to change, known groups validity (ability to differentiate between severity groups), and construct validity.
Read the detailed description

This study will engage up to 20 participants with TN through patient associations or HCPs. The study will be conducted in English Speaking countries.

The study comprises the following parts :

  • Participants Recruitment
  • Completion of the Diary
  • Qualitative interviews with participants
  • Analysis of qualitative research to assess content validity
  • Secondary analysis as a workshop with a panel of experts to finalize the diary The diary will be provided to each participant and to HCPs. Participants will be requested to follow the instructions, use the diary and provide their feedback on the diary.
03

Conditions studied

  • Trigeminal Neuralgia

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Adult patients or former patients with diagnosed trigeminal neuralgia

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female aged of 40 years or more.
  • Must be able to read, write, and speak English to complete the consent process and participate in an interview.
  • Able and willing to provide consent for participation in the study, and to allow the study team to access their data entries including audio or video recordings. - - Participant with a current or previous diagnosis of TN
  • Willing to participate in up to 30 minutes remote interviews or in-person interview (this interview will be recorded by the HCP)
  • Committ to fill in the diary according to the HCP instruction

Exclusion criteria

Exclusion Criteria:

  • Not applicable
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (actual)
Patient registry
No

Interventions

  • OtherPain Diary use

    Validation of a pain diary specifically designed to capture pain dimensions of Trigeminal Neuralgia

06

What researchers measure

Primary outcomes

  1. Measure of pain associated with Trigeminal Neuralgia

    Use of the TN Pain questionnaire to measure the pain associated with trigeminal neuralgia

    Time frame: 2 weeks

  2. Concept elicitation of the diary content

    During an interview, assess if the questionnaire is comprehensive, clear and correctly captures patients experience

    Time frame: 1 day

07

Study locations

2 sites
  • Kainzen Centre
    La Jolla, California 92037, United States
  • ULC Research
    London, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Aug 2023, 21 months.

Of 19 observational studies under Trigeminal Neuralgia, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2022
First posted
Aug 31, 2023
StartActual
Nov 20, 2021
Primary completionActual
Aug 31, 2023
CompletionActual
Aug 31, 2023
Last update
Dec 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06019338
Lead sponsor
Noema Pharma AG
Responsible party
Sponsor
First posted
Aug 31, 2023
Start date
Nov 20, 2021
Primary completion
Aug 31, 2023
Completion
Aug 31, 2023
Last update
Dec 10, 2024

Study contacts

Clinical Director
study director · Noema Pharma AG

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion